Cargando…

Next Generation Therapeutics for the Treatment of Myelofibrosis

Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia. JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Douglas, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146033/
https://www.ncbi.nlm.nih.gov/pubmed/33925695
http://dx.doi.org/10.3390/cells10051034